scholarly journals THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma

Oncotarget ◽  
2021 ◽  
Vol 12 (22) ◽  
pp. 2266-2272
Author(s):  
Phyllis A. Gimotty ◽  
Jacob E. Till ◽  
Shirsa Udgata ◽  
Naomi Takenaka ◽  
Stephanie S. Yee ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Prognostic Biomarker ◽  
Ductal Adenocarcinoma

scholarly journals Calcium-activated chloride channel regulator 1 as a prognostic biomarker in pancreatic ductal adenocarcinoma

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Dingyuan Hu ◽  
Daniel Ansari ◽  
Qimin Zhou ◽  
Agata Sasor ◽  
Katarzyna Said Hilmersson ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Chloride Channel ◽  
Prognostic Biomarker ◽  
Ductal Adenocarcinoma

Reduced expression of desmocollin 2 is an independent prognostic biomarker for shorter patients survival in pancreatic ductal adenocarcinoma

2011 ◽  
Vol 64 (11) ◽  
pp. 990-994 ◽  
Author(s):  
Z. Hamidov ◽  
A. Altendorf-Hofmann ◽  
Y. Chen ◽  
U. Settmacher ◽  
I. Petersen ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Prognostic Biomarker ◽  
Ductal Adenocarcinoma

scholarly journals Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma

2020 ◽  
Vol 40 (7) ◽  
Author(s):  
Xin Zhao ◽  
Di Cao ◽  
Zhangyong Ren ◽  
Zhe Liu ◽  
Shaocheng Lv ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Promoter Methylation ◽  
Methylation Level ◽  
Cox Regression ◽  
Prognostic Biomarker ◽  
Dipeptidyl Peptidase ◽  
Ductal Adenocarcinoma ◽  
Gene Promoters ◽  
Cox Regression Analysis

Abstract Background: Hypermethylation of gene promoters plays an important role in tumorigenesis. The present study aimed to identify and validate promoter methylation-driven genes (PMDGs) for pancreatic ductal adenocarcinoma (PDAC). Methods: Based on GSE49149 and the PDAC cohort of The Cancer Genome Atlas (TCGA), differential analyses of promoter methylation, correlation analysis, and Cox regression analysis were performed to identify PMDGs. The promoter methylation level was assessed by bisulfite sequencing polymerase chain reaction (BSP) in paired tumor and normal tissues of 72 PDAC patients. Kaplan−Meier survival analyses were performed to evaluate the clinical value of PMDGs. Results: In GSE49149, the β-value of the dipeptidyl peptidase like 6 (DPP6) promoter was significantly higher in tumor compared with normal samples (0.50 vs. 0.24, P<0.001). In the PDAC cohort of TCGA, the methylation level of the DPP6 promoter was negatively correlated with mRNA expression (r = −0.54, P<0.001). In a multivariate Cox regression analysis, hypermethylation of the DPP6 promoter was an independent risk factor for PDAC (hazard ratio (HR) = 543.91, P=0.002). The results of BSP revealed that the number of methylated CG sites in the DPP6 promoter was greater in tumor samples than in normal samples (7.43 vs. 2.78, P<0.001). The methylation level of the DPP6 promoter was moderately effective at distinguishing tumor from normal samples (area under ROC curve (AUC) = 0.74, P<0.001). Hypermethylation of the DPP6 promoter was associated with poor overall (HR = 3.61, P<0.001) and disease-free (HR = 2.01, P=0.016) survivals for PDAC patients. Conclusion: These results indicate that DPP6 promoter methylation is a potential prognostic biomarker for PDAC.

scholarly journals Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma

2012 ◽  
Vol 103 (9) ◽  
pp. 1714-1721 ◽  
Author(s):  
Hye Won Chung ◽  
Jong-Baeck Lim ◽  
Sunphil Jang ◽  
Kyong Joo Lee ◽  
Kyung Hwa Park ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Prognostic Biomarker ◽  
High Mobility ◽  
High Mobility Group ◽  
Ductal Adenocarcinoma

Paraneoplastic Ma Antigen–Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma

Pancreas ◽  
2015 ◽  
Vol 44 (1) ◽  
pp. 106-115 ◽  
Author(s):  
Yuko Kuwae ◽  
Anna Kakehashi ◽  
Kenichi Wakasa ◽  
Min Wei ◽  
Shotaro Yamano ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Prognostic Biomarker ◽  
Ductal Adenocarcinoma

scholarly journals Low Serum miR-607 Level as a Potential Diagnostic and Prognostic Biomarker in Patients of Pancreatic Ductal Adenocarcinoma: A Preliminary Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Dawei Jiang ◽  
Xiangfei Yuan ◽  
Jianqi Ni ◽  
Lan Shen ◽  
Min Cai ◽  
...  
Keyword(s):  
Cell Migration ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Epithelial Mesenchymal Transition ◽  
Prognostic Biomarker ◽  
Ductal Adenocarcinoma ◽  
Migration And Invasion ◽  
Roc Curve Analysis ◽  
Mesenchymal Transition ◽  
Low Serum ◽  
Better Than

Background. One of the microRNAs (miRNAs) known to be associated with cancer development is miR-607. The aim of this study is to investigate the clinical significance and diagnostic and prognostic value of miR-607 and to explore its potential role in pancreatic ductal adenocarcinoma (PDAC). Methods. The expression levels of miR-607 were assessed by quantitative real-time polymerase chain reaction (qRT-PCR). The correlation between miR-607 expression and clinical characteristics was analyzed by the Chi-square test. Overall survival (OS) and progression-free survival (PFS) were evaluated via the Kaplan–Meier method, and the association between miR-607 expression and OS was investigated by the Cox proportional hazard analysis. The diagnostic value was estimated via receiver operating characteristic (ROC) curve analysis. The effect of miR-607 overexpression on cell migration, invasion, and epithelial-mesenchymal transition (EMT) was determined by wound-healing, Transwell invasion, and Western blotting assays. Results. miR-607 levels were downregulated in PDAC tumor tissues compared with normal tissues. Also, low miR-607 levels were observed in serum samples from PDAC patients than that in healthy controls. The miR-607 level was found to be closely correlated with lymphatic metastasis and liver metastasis, perineural invasion, and OS and PFS, and the low miR-607 level was an independent prognostic factor for the poor OS of PDAC patients. Furthermore, the area under the curve (AUC) of serum miR-607 for discriminating PDAC patients was 0.785 with a sensitivity of 0.647 and a specificity of 0.772, which was better than those for CA19-9 (AUC: 0.702, sensitivity: 0.607, specificity: 0.736) and CEA (AUC: 0.648, sensitivity: 0.542, specificity: 0.670). The AUC (0.863), sensitivity (0.766), and specificity (0.831) of their combination in the diagnosis of PDAC were better than those for alone. Moreover, ectopic overexpression of miR-607 could inhibit cell migration and invasion of BxPc-3 and PANC-1 cells by decreasing EMT ability. Conclusions. Low serum miR-607 level may serve as a potential diagnostic and prognostic biomarker through regulation of tumor metastasis in PDAC patients.

Sign in / Sign up

Export Citation Format

Share Document